Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
|Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage I Prostate Cancer Stage IIA Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer||Biological: bevacizumab Other: laboratory biomarker analysis||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Phase II Trial of Bevacizumab in PSA Relapse Androgen Independent Prostate Cancer (AVF3952sn)|
- PSA Response Rate With Bevacizumab Therapy in Androgen Independent Non-metastatic Prostate Cancer [ Time Frame: An average every 6 weeks for up to 3 months ]Response rates will be summarized by point estimates and Wilson type 80% confidence intervals.
- Toxicities Associated With Bevacizumab Therapy [ Time Frame: An average of every 2 weeks while on therapy ]Toxicity rates will be summarized by point estimates and Wilson type 80% confidence intervals. Toxicities will be graded per the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), and PSA response will be determined as per PSA Working Group response criteria. Censored time to PSA progression will be estimated with standard Kaplan-Meier methodology.
- Time to PSA Progression (TTPP) [ Time Frame: An average every 6 weeks for up to 3 months ]TTPP will be measured from protocol registration to appearance of PSA progression as defined by the criteria of the PSA Working Group response criteria. The end point for progression will be calculated at the time a 25% increase in PSA has been achieved. PSA velocity will also be calculated as change in PSA doubling time pre and post therapy and the rate of PSA rise pre- and post-therapy.
- Overall Survival of Androgen Independent Non-metastatic Prostate Cancer Patients Treated With Bevacizumab [ Time Frame: Every 3 months ]
- The Change in PSA Velocity With Bevacizumab Therapy in Androgen Independent Non-metastatic Prostate Cancer [ Time Frame: Baseline, every 6 weeks while on therapy, and then every 3 months thereafter ]
- Time to Distant Metastatic Disease [ Time Frame: Every 3 months ]
- Circulating Tumor Cell Count [ Time Frame: Baseline, at week 12 ]
- Changes in Levels of N Terminal Collagen Peptide and Bone-specific Alkaline Phosphatase With Bevacizumab Therapy [ Time Frame: Baseline, week 7 or 12, and post-therapy ]
- Correlation of Urine NTX and Serum BSAP Levels With Time to PSA Progression [ Time Frame: Baseline, week 7 or 12 and post-therapy ]
|Study Start Date:||May 2007|
|Study Completion Date:||June 2012|
|Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Experimental: Treatment (monoclonal antibody, antiangiogenesis)
Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
Other Names:Other: laboratory biomarker analysis
I. The rate of prostate-specific antigen (PSA) response with avastin (bevacizumab) therapy in androgen independent non-metastatic prostate cancer.
II. Toxicities associated with avastin therapy. III. Time to PSA progression.
I. Overall survival of androgen independent non-metastatic prostate cancer patients treated with avastin.
II. The change in PSA velocity with avastin therapy in androgen-independent non-metastatic prostate cancer.
III. Time to distant metastatic disease. IV. Circulating tumor cell count. V. Changes in levels of N terminal collagen peptide and bone-specific alkaline phosphatase with avastin therapy.
VI. Correlation of crosslinked N-telopeptide of type I collagen (NTX) and serum B-Cell-Specific Activator Protein (BSAP) levels with time to PSA progression.
Patients receive bevacizumab intravenously (IV) over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01656304
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201|
|Henry Ford Hospital|
|Detroit, Michigan, United States, 48202|
|Principal Investigator:||Ulka Vaishampayan||Barbara Ann Karmanos Cancer Institute|